Faeth Therapeutics, Inc. (FTH): Cash & Equivalents
$8.67M
As of 2025-12-31
$26.90M
As of 2026-06-30
-21.3%
3-year compound annual growth
-12.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.67M | -13.3% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $9.99M | -23.2% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $13.01M | -26.9% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $17.80M | +148.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $7.16M | -56.9% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $16.60M | n/a | 2022-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $8.67M | -13.3% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $8.24M | -8.5% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $20.84M | +100.6% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $8.88M | +107.5% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $15.48M | -56.6% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $3.21M | -75.0% |
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $10.49M | n/m |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.70M | +129.3% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $21.03M | +290.8% |
Compare FTH, CRVO, GANX, MBRX side by side · Screen every company in Pharmaceutical Preparations ↗